+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating how well the medicine zasocitinib works and its safety in children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis. The study is conducted in two parts Part A includes both children and teenagers, while Part B includes only children. Initially, only teenagers meeting specific study rules can join, with children joining after sufficient data is available from other studies. In Part A, participants are randomly assigned to receive either zasocitinib or a matching placebo orally once daily for the first 16 weeks. After this, all receive zasocitinib until the study ends. In Part B, all children receive weight-based oral doses of zasocitinib throughout the study. The treatment lasts up to 208 weeks, with a total study participation time of up to 217 weeks, including screening and safety follow-up. Participants will visit the study site multiple times during the study for assessments, including skin evaluations and measuring drug levels in the blood. Researchers will monitor how well participants respond using various psoriasis severity scales and quality of life questionnaires. A safety follow-up period of 4 weeks occurs after treatment ends to monitor any ongoing effects. The study aims to understand zasocitinibs effects and safety in this young population over a long term.

Age: 4Years - 17YearsAll GendersPhase 3
39 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of different doses of IMG-007 compared to placebo in adults with moderate-to-severe active atopic dermatitis. This Phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to understand how well IMG-007 works and its safety profile over a period of up to 48 weeks. Participants will receive subcutaneous injections of IMG-007 or placebo according to the study protocol. The study includes multiple dose regimens of IMG-007 and placebo groups, with some placebo participants crossing over to receive IMG-007 later. Treatments follow a parallel group design where different groups receive different doses or placebo. During the study, participants will undergo assessments including Eczema Area and Severity Index EASI scoring and Investigator Global Assessment for Atopic Dermatitis vIGA-AD at baseline and Week 24. Researchers will monitor treatment-emergent adverse events throughout the study. Participants will be followed for up to 48 weeks to evaluate changes in skin condition and safety outcomes during and after treatment.

Age: 18Years - 74YearsAll GendersPhase 2
30 locations
P

Actively Recruiting

Researchers are studying patients with advanced or metastatic non-small cell lung cancer NSCLC to create control groups using current and future patient data. The study aims to generate precision external control arms by observing different patient cohorts categorized by specific genetic mutations and treatment lines. This observational study helps understand treatment responses in real-world settings without assigning specific therapies. Participants are grouped based on their treatment regimens and genetic profiles, such as those starting first-line immune checkpoint inhibitor therapies, patients with actionable EGFR mutations, KRAS mutations, or varying PD-L1 expression levels. The study observes patients receiving standard therapies, such as platinum doublets, targeted agents like osimertinib or lazertinib, or other recommended treatments across different lines of therapy. The study spans from January 2026 to April 2029. During the study, participants response rates to therapies will be assessed, focusing on Objective Response Rate ORR in metastatic NSCLC patients treated in second or third line settings. Secondary measures include progression-free survival, overall survival, and time to next treatment. Participants will be monitored through clinical evaluations and imaging studies to track disease status. This study involves no investigational treatments and aims to gather data from real-world clinical practice over several years.

Age: 18Years +All Genders
11 locations
L

Actively Recruiting

This research aims to evaluate the long-term safety and effectiveness of ORKA-001 in adults who have moderate-to-severe plaque psoriasis and previously took part in an Oruka Therapeutics study. It is an open-label extension study where all participants receive the study drug to monitor ongoing treatment effects and safety over an extended period. Participants will receive ORKA-001 as a subcutaneous injection through different dosing schedules once a year high or low dose, twice a year, or no drug until meeting specific response criteria. The treatment period can last up to about 96 weeks, followed by a post-treatment follow-up lasting approximately 48 weeks after the last study visit. During the study, participants will undergo safety monitoring, including checking for adverse events. Effectiveness will be assessed by measuring skin condition improvements using tools like the Psoriasis Area and Severity Index PASI and Investigators Global Assessment IGA. The team will track these results over time to understand how participants maintain their skin improvements and overall treatment tolerance.

Age: 18Years +All GendersPhase 2
39 locations
M

Actively Recruiting

Researchers are evaluating a non-invasive device designed to measure flow in cerebrospinal fluid CSF shunts in patients who already have an implanted shunt. The study focuses on hydrocephalus and aims to collect longitudinal data on shunt function using this new wireless thermal anisotropy measurement device. The study is interventional in nature but does not involve active treatment changes. Participants will wear the thermal anisotropy measurement device, which is placed on the skin over the implanted CSF shunt. This device uses a thermal actuator and temperature sensors to assess the flow through the shunt without requiring invasive procedures. The study includes a feasibility assessment cohort, and the device data acquisition is non-interventional. Participants may use the device at home or in an inpatient setting, with remote or in-person follow-up during a 30-day measurement period. During the study, researchers will monitor skin temperature and acceleration data for up to 90 days to assess device performance. Participants will be asked to communicate and document shunt symptoms in English, and verbal assent is required for minors 12 years and older. The study includes safety monitoring and follow-up to ensure data reliability and participant well-being. The total duration of participation varies depending on the setting and follow-up schedule.

Age: 5Years - 80YearsAll GendersPhase Not Applicable
4 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 in people with myelofibrosis or myelodysplastic syndrome who also have anemia. This phase 1b2a open-label study aims to understand how DISC-0974 affects hematologic response in these participants, including its impact on anemia and transfusion dependence. DISC-0974 is given as a subcutaneous injection every four weeks during both the phase 1b dose-escalation and phase 2 expansion parts of the study. The study evaluates different cohorts based on transfusion dependence and anemia status, with doses administered repeatedly up to day 169. Participants continue stable dosing of other therapies for myelofibrosis as allowed, and certain washout periods are required before screening. Participants will be involved in regular assessments including blood and urine tests to monitor safety and treatment effects from day 1 through day 169. Researchers measure anemia response, transfusion independence, hematologic parameters, pharmacodynamics markers, and safety outcomes such as vital signs and adverse events. The study includes monitoring of quality of life related to anemia and fatigue. Overall participation may last several months, with detailed evaluations during treatment.

Age: 18Years +All GendersPhase 1Phase 2
35 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a reformulated Levulan Kerastick solution combined with photodynamic therapy PDT to treat actinic keratosis AK on the face or bald scalp. This Phase 3, randomized, multi-center, evaluator-blind, vehicle-controlled study focuses on adults with 4 to 8 mild to moderate AK lesions. The study aims to measure the complete clearance rate of these lesions at 12 weeks and also assesses other outcomes like partial clearance, lesion count changes, recurrence, cosmetic results, and patient satisfaction. Participants are assigned to one of four groups based on whether they receive the active drug or a vehicle solution and on two different incubation times before blue light application. Up to two PDT sessions may be given depending on lesion clearance. The active drug is a topical solution of aminolevulinic acid hydrochloride ALA HCl 20%, compared to a vehicle solution without the active ingredient. A blue light PDT device is used during the treatment. During the study, participants will have clinic visits to assess lesion clearance and safety through evaluations of skin reactions, vital signs, and lab tests. Researchers will track outcomes at weeks 4, 8, 12, 20, and 24, including lesion clearance rates, cosmetic response, and patient satisfaction. The total study duration extends through these follow-up assessments, with safety monitoring throughout and a final evaluation at week 24.

Age: 18Years - 85YearsAll GendersPhase 3
12 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a new formulation of Levulan Kerastick combined with photodynamic therapy PDT to treat actinic keratosis AK on the upper arms. This Phase 3, randomized, multi-center, and evaluator-blind study compares this treatment to a vehicle control in adults with mild to moderate AK lesions. The goal is to see how well the treatment clears the lesions and to assess its safety. Participants will be randomly assigned to receive either the Levulan Kerastick solution or a vehicle solution applied to the skin, followed by an incubation period under occlusion and exposure to blue light using a specialized device. Up to two PDT sessions may be given depending on how well lesions clear. The study includes multiple time points for assessing lesion clearance, cosmetic outcomes, patient satisfaction, and recurrence rates. Throughout the study, participants will be monitored through visits where the skin lesions are evaluated, safety assessments are made including skin reactions and lab tests, and patient feedback is collected. The primary outcome focuses on the complete clearance rate of AK lesions at Week 12. Secondary outcomes involve lesion clearance at various weeks up to 24, cosmetic responses, and recurrence. The total study duration includes treatment and follow-up assessments extending to Week 24.

Age: 18Years - 85YearsAll GendersPhase 3
22 locations
T

Actively Recruiting

Researchers are evaluating participants with cancer in a non-interventional, multicenter, multicohort study to observe plasma circulating tumor DNA ctDNA biomarker changes over time. This study aims to gather valuable data alongside participants standard cancer treatments to better understand cancer biology. The study is sponsored by Tempus AI and focuses on various cancer types including KRAS mutated colorectal, pancreatic, and lung cancers, gastric cancer, metastatic prostate cancer, and others. Participants in this observational study will not receive any study interventions or treatments. Instead, they will provide blood samples at specific time points throughout their treatment journey for ctDNA analysis and other molecular studies. The study includes multiple cohorts representing different cancer types, but no additional therapies are assigned by the study team. During the study, participants will undergo regular blood draws to monitor ctDNA levels at baseline, during treatment, and after treatment for up to five years. Researchers will also generate DNA, RNA, immune, and other molecular datasets from these samples. The study involves no experimental treatments, focusing on data collection to support future cancer research. Participation may last up to five years, with ongoing monitoring of biomarker changes and data generation.

Age: 18Years - 99YearsAll Genders
32 locations